ARTICLE | Product Development
Rethinking RECIST for immunotherapies
How companies, FNIH are working to find new IO response criteria
November 17, 2018 3:17 AM UTC
Updated on Nov 26, 2019 at 5:09 PM UTC
Momentum is growing for new tumor response criteria that better reflect the benefits of cancer immunotherapies, with FNIH, companies and FDA all pushing for validation of these criteria.
At a Nov. 9 workshop co-hosted by the Society for Immunotherapy of Cancer (SITC) and FDA, the agency highlighted its concerns over the possibility that benefits of immunotherapies aren’t fully captured by existing RECIST 1.1 criteria, and what it would like to see companies do to test new criteria...